Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Profit After Tax (2016 - 2025)

Acro Biomedical has reported Profit After Tax over the past 10 years, most recently at $42526.0 for Q4 2025.

  • Quarterly results put Profit After Tax at $42526.0 for Q4 2025, up 498.44% from a year ago — trailing twelve months through Dec 2025 was -$101146.0 (down 139.13% YoY), and the annual figure for FY2025 was -$101146.0, down 139.13%.
  • Profit After Tax for Q4 2025 was $42526.0 at Acro Biomedical, up from -$117809.0 in the prior quarter.
  • Over the last five years, Profit After Tax for ACBM hit a ceiling of $42526.0 in Q4 2025 and a floor of -$4.0 million in Q3 2022.
  • Median Profit After Tax over the past 5 years was -$456248.0 (2021), compared with a mean of -$1.6 million.
  • Biggest five-year swings in Profit After Tax: crashed 6503.69% in 2022 and later surged 498.44% in 2025.
  • Acro Biomedical's Profit After Tax stood at -$3.9 million in 2021, then dropped by 2.12% to -$3.9 million in 2022, then soared by 99.54% to -$18240.0 in 2023, then surged by 41.49% to -$10673.0 in 2024, then surged by 498.44% to $42526.0 in 2025.
  • The last three reported values for Profit After Tax were $42526.0 (Q4 2025), -$117809.0 (Q3 2025), and -$15562.0 (Q2 2025) per Business Quant data.